Big Pharma Players Have Initiated Product Development Programs, Having Invested Significaby Roots Analysis Roots Analysis provides market research and consul
Over the years, various well-established big pharmaceutical players have marked their presence in the field of liquid biopsy, by either expanding their respective product portfolios, partnering with other companies, or investing in liquid biopsy development initiatives. most of the companies that Merck has partnered or invested in have their products commercialized. Further, Roche is the only company that is directly involved in the development of liquid biopsies and has three liquid biopsy products in its portfolio.
In addition, Johnson and Johnson has actively invested in two companies, namely GRAIL and Inivata, which are working in the liquid biopsy domain. In fact, Johnson and Johnson was one of the key investors in GRAIL’s series B venture capital round; the latter company had raised a total of USD 900 million in this funding round. Moreover, in 2016, Johnson and Johnson’s division, Janssen Diagnostics sold its FDA-approved CellSearch CTC capture system to Menarini Silicon Biosystems. It is worth mentioning that majority of the big pharma players appear to be interested in the products that can be used for diagnosis of more than one cancer indication; some of the key indications for which liquid biopsies are being developed include lung cancer, colorectal cancer, and breast cancer.
Majority of the big pharma players (9) have shown interest in products designed for treatment selection. This is followed by products for diagnosis / early diagnosis; seven big pharma companies are focusing on products for diagnosis / early diagnosis.
It is worth mentioning that Merck and Bristol-Myers Squibb have partnered or invested in companies that have products designed for all of the three key application areas (namely diagnosis / early diagnosis, treatment selection, and patient monitoring). The companies that Merck has collaborated with include (in alphabetical order) Amoy Diagnostics (in 2016), Biocartis (in 2016), and Guardant Health (in 2017).
Created on Jun 24th 2020 08:21. Viewed 96 times.